Живи долго! Научный подход к долгой молодости и здоровью

4044

Fischer ME, Schubert CR, Nondahl DM, et al. Subclinical atherosclerosis and increased risk of hearing impairment. Atherosclerosis. 2015;238(2):344–9. https://pubmed.ncbi.nlm.nih.gov/25555266/

4045

Erkan AF, Beriat GK, Ekici B, Dogan C, Kocatürk S, Töre HF. Link between angiographic extent and severity of coronary artery disease and degree of sensorineural hearing loss. Herz. 2015;40(3):481–6. https://pubmed.ncbi.nlm.nih.gov/24049023/

4046

Sikora MA, Morizono T, Ward WD, Paparella MM, Leslie K. Diet-induced hyperlipidemia and auditory dysfunction. Acta Oto-Laryngologica. 1986;102(5–6):372–81. https://pubmed.ncbi.nlm.nih.gov/3788535/

4047

Saito T, Sato K, Saito H. An experimental study of auditory dysfunction associated with hyperlipoproteinemia. Arch Otorhinolaryngol. 1986;243(4):242–5. https://pubmed.ncbi.nlm.nih.gov/3778299/

4048

Turpeinen O, Roine P, Pekkarinen M, et al. Effect on serum-cholesterol level of replacement of dietary milk fat by soybean oil. Lancet. January 23, 1960;196–9. https://pubmed.ncbi.nlm.nih.gov/13839984/

4049

Hearing loss and coronary heart disease. JAMA. 1965;194(4):452 https://pubmed.ncbi.nlm.nih.gov/5897421/

4050

Puga AM, Pajares MA, Varela-Moreiras G, Partearroyo T. Interplay between nutrition and hearing loss: state of art. Nutrients. 2018;11(1):E35. https://pubmed.ncbi.nlm.nih.gov/30586880/

4051

Hearing loss and coronary heart disease. JAMA. 1965;194(4):452. https://pubmed.ncbi.nlm.nih.gov/5897421/

4052

Rosen S, Olin P, Rosen HV. Dietary prevention of hearing loss. Acta Oto-Laryngologica. 1970;70(4):242–7. https://pubmed.ncbi.nlm.nih.gov/5491161/

4053

Nobus D. The madness of Princess Alice: Sigmund Freud, Ernst Simmel and Alice of Battenberg at Kurhaus Schloß Tegel. Hist Psychiatry. 2020;31(2):147–62. https://pubmed.ncbi.nlm.nih.gov/31969019/

4054

Brown-Séquard. Note on the effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet. 1889;134(3438):105–7. https://www.sciencedirect.com/science/article/abs/pii/S0140673600641181

4055

Kahn A. Regaining lost youth: the controversial and colorful beginnings of hormone replacement therapy in aging. J Gerontol A Biol Sci Med Sci. 2005;60(2):142–7. https://pubmed.ncbi.nlm.nih.gov/15814854/

4056

Blue E. The strange career of Leo Stanley: remaking manhood and medicine at San Quentin State Penitentiary, 1913–1951. Pac Hist Rev. 2009;78(2):210–41. https://www.researchgate.net/publication/236335739_The_Strange_Career_of_Leo_Stanley_Remaking_Manhood_and_Medicine_at_San_Quentin_State_Penitentiary_1913-1951

4057

Perls TT. Anti-aging quackery: human growth hormone and tricks of the trade – more dangerous than ever. J Gerontol A Biol Sci Med Sci. 2004;59(7):682–91. https://pubmed.ncbi.nlm.nih.gov/15304532/

4058

Irwig MS, Fleseriu M, Jonklaas J, et al. Off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements: risks and costs of a growing problem. Endocr Pract. 2020;26(3):340–53. https://pubmed.ncbi.nlm.nih.gov/32163313/

4059

Regelson W. Growth hormone use. Science. 1987;235(4784):14c-5c. https://pubmed.ncbi.nlm.nih.gov/17769289/

4060

Barkan AL. Growth hormone as an anti-aging therapy – do the benefits outweigh the risks? Nat Clin Pract Endocrinol Metab. 2007;3(7):508–9. https://pubmed.ncbi.nlm.nih.gov/17534272/

4061

Irwig MS, Fleseriu M, Jonklaas J, et al. Off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements: risks and costs of a growing problem. Endocr Pract. 2020;26(3):340–53. https://pubmed.ncbi.nlm.nih.gov/32163313/

4062

Mullur RS. Making a difference in adrenal fatigue. Endocr Pract. 2018;24(12):1103–5. https://pubmed.ncbi.nlm.nih.gov/30289314/

4063

Cadegiani FA, Kater CE. Adrenal fatigue does not exist: a systematic review. BMC Endocr Disord. 2016;16(1):48. https://pubmed.ncbi.nlm.nih.gov/27557747/

4064

Nippoldt T. Mayo Clinic office visit. Adrenal fatigue: an interview with Todd Nippoldt, M.D. Mayo Clin Womens Healthsource. 2010;14(3):6. https://pubmed.ncbi.nlm.nih.gov/20110864/

4065

Chimote BN, Chimote NM. Dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) in mammalian reproduction: known roles and novel paradigms. Vitam Horm. 2018;108:223–50. https://pubmed.ncbi.nlm.nih.gov/30029728/

4066

Kim MJ, Morley JE. The hormonal fountains of youth: myth or reality? J Endocrinol Invest. 2005;28(11 Suppl Proceedings):5–14. https://pubmed.ncbi.nlm.nih.gov/16760618/

4067

Peixoto C, Carrilho CG, Barros JA, et al. The effects of dehydroepiandrosterone on sexual function: a systematic review. Climacteric. 2017;20(2):129–37. https://pubmed.ncbi.nlm.nih.gov/28118059/

4068

Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014;74(11):1195–207. https://pubmed.ncbi.nlm.nih.gov/25022952/

4069

ConsumerLab.com tests DHEA supplements, warns of differences in dose and price. ConsumerLab.com. https://www.consumerlab.com/news/dhea-dose-price/07–22–2015/. Published July 22, 2015. Accessed May 5, 2022.; https://www.consumerlab.com/news/dhea-dose-price/07-22-2015

4070

Celec P, Stárka L. Dehydroepiandrosterone – is the fountain of youth drying out? Physiol Res. 2003;52(4):397–407. https://pubmed.ncbi.nlm.nih.gov/12899651/

4071

Peixoto C, Carrilho CG, Barros JA, et al. The effects of dehydroepiandrosterone on sexual function: a systematic review. Climacteric. 2017;20(2):129–37. https://pubmed.ncbi.nlm.nih.gov/28118059/

4072

Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod. 2010;25(10):2496–500. https://pubmed.ncbi.nlm.nih.gov/22456062/

4073

Tartagni M, Cicinelli MV, Baldini D, et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reprod Biol Endocrinol. 2015;13:18. https://ncbi.nlm.nih.gov/pmc/articles/PMC4355976/

4074

Thompson RD, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. J AOAC Int. 2000;83(4):847–57. https://pubmed.ncbi.nlm.nih.gov/10995111/

4075

Trichopoulou A, Bamia C, Kalapothaki V, Spanos E, Naska A, Trichopoulos D. Dehydroepiandrosterone relations to dietary and lifestyle variables in a general population sample. Ann Nutr Metab. 2003;47(3–4):158–64. https://pubmed.ncbi.nlm.nih.gov/12743468/

4076

Remer T, Pietrzik K, Manz F. The short-term effect of dietary pectin on plasma levels and renal excretion of dehydroepiandrosterone sulfate. Z Ernahrungswiss. 1996;35(1):32–8. https://pubmed.ncbi.nlm.nih.gov/8776832/

4077

Remer T, Pietrzik K, Manz F. Short-term impact of a lactovegetarian diet on adrenocortical activity and adrenal androgens. J Clin Endocrinol Metab. 1998;83(6):2132–7. https://pubmed.ncbi.nlm.nih.gov/9626151/

4078

Hill P, Wynder EL, Garbaczewski L, Walker AR. Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer. Cancer Res. 1982;42(9):3864–9. https://pubmed.ncbi.nlm.nih.gov/6179613/

4079

Hill P, Garbaczewski L, Helman P, Huskisson J, Sporangisa E, Wynder EL. Diet, lifestyle, and menstrual activity. Am J Clin Nutr. 1980;33(6):1192–8. https://pubmed.ncbi.nlm.nih.gov/7386408/

4080

Remer T, Pietrzik K, Manz F. Short-term impact of a lactovegetarian diet on adrenocortical activity and adrenal androgens. J Clin Endocrinol Metab. 1998;83(6):2132–7. https://pubmed.ncbi.nlm.nih.gov/9626151/

4081

Grande M, Borobio V, Jimenez JM, et al. Antral follicle count as a marker of ovarian biological age to reflect the background risk of fetal aneuploidy. Hum Reprod. 2014;29(6):1337–43. https://pubmed.ncbi.nlm.nih.gov/24682614/

4082

Bozdag G, Calis P, Zengin D, Tanacan A, Karahan S. Age related normogram for antral follicle count in general population and comparison with previous studies. Eur J Obstet Gynecol Reprod Biol. 2016;206:120–4. https://pubmed.ncbi.nlm.nih.gov/27689809/

4083

Souter I, Chiu YH, Batsis M, et al. The association of protein intake (amount and type) with ovarian antral follicle counts among infertile women: results from the EARTH prospective study cohort. BJOG. 2017;124(10):1547–55. https://pubmed.ncbi.nlm.nih.gov/28278351/

4084

Hartmann S, Lacorn M, Steinhart H. Natural occurrence of steroid hormones in food. Food Chem (Oxf). 1998;62(1):7–20. https://www.sciencedirect.com/science/article/abs/pii/S0308814697001507?via%3Dihub

4085

Brinkman MT, Baglietto L, Krishnan K, et al. Consumption of animal products, their nutrient components and postmenopausal circulating steroid hormone concentrations. Eur J Clin Nutr. 2010;64(2):176–83. https://pubmed.ncbi.nlm.nih.gov/19904296/

4086

Andersson AM, Skakkebaek NE. Exposure to exogenous estrogens in food: possible impact on human development and health. Eur J Endocrinol. 1999;140(6):477–85. https://pubmed.ncbi.nlm.nih.gov/10366402/

4087

Souter I, Chiu YH, Batsis M, et al. The association of protein intake (amount and type) with ovarian antral follicle counts among infertile women: results from the EARTH prospective study cohort. BJOG. 2017;124(10):1547–55. https://pubmed.ncbi.nlm.nih.gov/28278351/

4088

Lumsden MA, Sassarini J. The evolution of the human menopause. Climacteric. 2019;22(2):111–6. https://pubmed.ncbi.nlm.nih.gov/30712396/

4089

National Center for Health Statistics. Health, United States, 2010: With Special Feature on Death and Dying. https://www.cdc.gov/nchs/data/hus/hus10.pdf. Published February 2011. Accessed May 5, 2022.; https://www.cdc.gov/nchs/data/hus/hus10.pdf

4090

Llarena N, Hine C. Reproductive longevity and aging: geroscience approaches to maintain long-term ovarian fitness. J Gerontol A Biol Sci Med Sci. 2021;76(9):1551–60. https://pubmed.ncbi.nlm.nih.gov/32808646/

4091

Gagnon A. Natural fertility and longevity. Fertil Steril. 2015;103(5):1109–16. https://pubmed.ncbi.nlm.nih.gov/25934597/

4092

Giri R, Vincent AJ. Prevalence and risk factors of premature ovarian insufficiency/early menopause. Semin Reprod Med. 2020;38(4–05):237–46. https://pubmed.ncbi.nlm.nih.gov/33434933/

4093

Stanford JL, Hartge P, Brinton LA, Hoover RN, Brookmeyer R. Factors influencing the age at natural menopause. J Chronic Dis. 1987;40(11):995–1002. https://pubmed.ncbi.nlm.nih.gov/3654908/

4094

Boutot ME, Purdue-Smithe A, Whitcomb BW, et al. Dietary protein intake and early menopause in the Nurses’ Health Study II. Am J Epidemiol. 2018;187(2):270–7. https://pubmed.ncbi.nlm.nih.gov/28992246/

4095

Conway F. Menopause matters: attending to the vitality of older women. J Women Aging. 2020;32(5):489–90. https://pubmed.ncbi.nlm.nih.gov/33225875/

4096

Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019;46(3):501–14. https://pubmed.ncbi.nlm.nih.gov/31378291/

4097

Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. J Evid Based Integr Med. 2019;24:2515690X19829380. https://pubmed.ncbi.nlm.nih.gov/30868921/

4098

Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019;46(3):501–14. https://pubmed.ncbi.nlm.nih.gov/31378291/

4099

Pirhadi R, Sinai Talaulikar V, Onwude J, Manyonda I. It is all in the name: the importance of correct terminology in hormone replacement therapy. Post Reprod Health. 2020;26(3):142–6. https://pubmed.ncbi.nlm.nih.gov/32390508/

4100

Hunter MM, Huang AJ, Wallhagen MI. “I’m going to stay young”: belief in anti-aging efficacy of menopausal hormone therapy drives prolonged use despite medical risks. PLoS One. 2020;15(5):e0233703. https://pubmed.ncbi.nlm.nih.gov/32469976/

4101

Wilson RA, Wilson TA. The fate of the nontreated postmenopausal woman: a plea for the maintenance of adequate estrogen from puberty to the grave. J Am Geriatr Soc. 1963;11:347–62. https://pubmed.ncbi.nlm.nih.gov/14001078/

4102

Wilson RA, Wilson TA. The basic philosophy of estrogen maintenance. J Am Geriatr Soc.1972;20(11):521–3. https://pubmed.ncbi.nlm.nih.gov/5082121/

4103

Chew F, Wu X. Sources of information influencing the state-of-the-science gap in hormone replacement therapy usage. PLoS One. 2017;12(2):e0171189. https://pubmed.ncbi.nlm.nih.gov/28158240/

4104

Fugh-Berman A. The science of marketing: how pharmaceutical companies manipulated medical discourse on menopause. Women’s Reprod Health. 2015;2(1):18–23. https://www.tandfonline.com/doi/full/10.1080/23293691.2015.1039448

4105

Rubinstein H. Defining what is normal at menopause: how women’s and clinician’s different understandings may lead to a lack of provision for those in most need. Hum Fertil (Camb). 2014;17(3):218–22. https://pubmed.ncbi.nlm.nih.gov/24989874/

4106

Tatsioni A, Siontis GCM, Ioannidis JPA. Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. J Gen Intern Med. 2010;25(9):914–9. https://pubmed.ncbi.nlm.nih.gov/20425148/

4107

Rubinstein H. Defining what is normal at menopause: how women’s and clinician’s different understandings may lead to a lack of provision for those in most need. Hum Fertil (Camb). 2014;17(3):218–22. https://pubmed.ncbi.nlm.nih.gov/24989874/

4108

Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am. 2019;46(3):501–14. https://pubmed.ncbi.nlm.nih.gov/31378291/

4109

Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas. 2009;64(2):80–5. https://pubmed.ncbi.nlm.nih.gov/19709827/

4110

Auchincloss H, Haagensen CD. Cancer of the breast possibly induced by estrogenic substance. JAMA. 1940;114(16):1517–23. https://jamanetwork.com/journals/jama/article-abstract/1160126

4111

Anderson G, Cummings S, Freedman LS, et al. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61–109. https://pubmed.ncbi.nlm.nih.gov/9492970/

4112

Cummings SR. Evaluating the benefits and risks of postmenopausal hormone therapy. Am J Med. 1991;91(5B):14S-8S. https://pubmed.ncbi.nlm.nih.gov/1750410/

4113

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. https://pubmed.ncbi.nlm.nih.gov/12117397/

4114

Marsden J. Hormone replacement therapy and female malignancy: what has the Million Women Study added to our knowledge? J Fam Plann Reprod Health Care. 2007;33(4):237–43. https://pubmed.ncbi.nlm.nih.gov/17925102/

4115

Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12. https://pubmed.ncbi.nlm.nih.gov/15082697/

4116

Fugh-Berman A, Pearson C. The overselling of hormone replacement therapy. Pharmacotherapy. 2002;22(9):1205–8. https://pubmed.ncbi.nlm.nih.gov/12222561/

4117

Katz A. Observations and advertising: controversies in the prescribing of hormone replacement therapy. Health Care Women Int. 2003;24(10):927–39. https://pubmed.ncbi.nlm.nih.gov/14742130/

4118

Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA. 2004;292(16):1983–8. https://pubmed.ncbi.nlm.nih.gov/15507584/

4119

Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670–4. https://pubmed.ncbi.nlm.nih.gov/17442911/

4120

Fugh-Berman A. The science of marketing: how pharmaceutical companies manipulated medical discourse on menopause. Women’s Reprod Health. 2015;2(1):18–23. https://www.tandfonline.com/doi/full/10.1080/23293691.2015.1039448

4121

Roth JA, Etzioni R, Waters TM, et al. Economic return from the Women’s Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med. 2014;160(9):594–602. https://pubmed.ncbi.nlm.nih.gov/24798522/

4122

Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA. 2004;292(16):1983–8. https://pubmed.ncbi.nlm.nih.gov/15507584/

4123

Carstens AJ. HRT prescriptions linked to 25 % of breast cancers in California. S Afr Med J. 2009;99(5):280. https://pubmed.ncbi.nlm.nih.gov/19588781/

4124

Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold “HRT.” PLoS Med. 2010;7(9):e1000335. https://pubmed.ncbi.nlm.nih.gov/20838656/

4125

Fugh-Berman A, Scialli AR. Gynecologists and estrogen: an affair of the heart. Perspect Biol Med. 2006;49(1):115–30. https://pubmed.ncbi.nlm.nih.gov/16489281/

4126

Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold “HRT.” PLoS Med. 2010;7(9):e1000335. https://pubmed.ncbi.nlm.nih.gov/20838656/

4127

Egilman AC, Kesselheim AS, Krumholz HM, Ross JS, Kim J, Kapczynski A. Confidentiality orders and public interest in drug and medical device litigation. JAMA Intern Med. 2020;180(2):292–9. https://pubmed.ncbi.nlm.nih.gov/31657836/

4128

Fugh-Berman A, Scialli AR. Gynecologists and estrogen: an affair of the heart. Perspect Biol Med. 2006;49(1):115–30. https://pubmed.ncbi.nlm.nih.gov/16489281/

4129

Tatsioni A, Siontis GCM, Ioannidis JPA. Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. J Gen Intern Med. 2010;25(9):914–9. https://pubmed.ncbi.nlm.nih.gov/20425148/

4130

Fugh-Berman A, Pearson C. The overselling of hormone replacement therapy. Pharmacotherapy. 2002;22(9):1205–8. https://pubmed.ncbi.nlm.nih.gov/12222561/

4131

Akesson A, Weismayer C, Newby PK, Wolk A. Combined effect of low-risk dietary and lifestyle behaviors in primary prevention of myocardial infarction in women. Arch Intern Med. 2007;167(19):2122–7. https://pubmed.ncbi.nlm.nih.gov/17954808/

4132

American Academy of Family Physicians. Clinical preventative service recommendation: hormone replacement therapy. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/hrt.html. Accessed Aug 2, 2022.; https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/hrt.html

4133

Fick DM, Semla TP, Steinman M, et al. American Geriatrics Society 2019 updated AGS Beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. https://pubmed.ncbi.nlm.nih.gov/30693946/

4134

Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update. J Am Coll Cardiol. 2011;57(12):1404–23. https://pubmed.ncbi.nlm.nih.gov/21325087/

4135

Grossman DC, Curry SJ, Owens DK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. JAMA. 2017;318(22):2224–33. https://pubmed.ncbi.nlm.nih.gov/29677309/

4136

ACOG Committee Opinion No. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013;121(6):1407–10. https://pubmed.ncbi.nlm.nih.gov/23812486/

4137

Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978. https://pubmed.ncbi.nlm.nih.gov/15495039/

4138

Santoro N, Allshouse A, Neal-Perry G, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study (KEEPS). Menopause. 2017;24(3):238–46. https://pubmed.ncbi.nlm.nih.gov/27779568/

4139

Marjoribanks J, Farquhar CM, Roberts H, Lethaby A. Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women. Heart. 2018;104(2):93–5. https://pubmed.ncbi.nlm.nih.gov/28739806/

4140

Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:CD004143. https://pubmed.ncbi.nlm.nih.gov/28093732/

4141

Marjoribanks J, Farquhar CM, Roberts H, Lethaby A. Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women. Heart. 2018;104(2):93–5. https://pubmed.ncbi.nlm.nih.gov/28739806/

4142

Manson JE, Bassuk SS, Kaunitz AM, Pinkerton JV. The Women’s Health Initiative trials of menopausal hormone therapy: lessons learned. Menopause. 2020;27(8):918–28. https://pubmed.ncbi.nlm.nih.gov/32345788/

4143

Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010;28(1):81–90. https://pubmed.ncbi.nlm.nih.gov/20104432/

4144

Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978. https://pubmed.ncbi.nlm.nih.gov/15495039/